Baader Bank Aktiengesellschaft Buys 12,598 Shares of Boston Scientific Corporation $BSX

Baader Bank Aktiengesellschaft raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 112.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,784 shares of the medical equipment provider’s stock after acquiring an additional 12,598 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Boston Scientific were worth $2,241,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BSX. Murphy & Mullick Capital Management Corp lifted its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter worth $26,000. United Community Bank increased its position in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Colonial Trust Co SC increased its position in shares of Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank increased its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BSX shares. TD Cowen cut their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. Jefferies Financial Group reduced their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research note on Thursday, April 23rd. Finally, Wells Fargo & Company decreased their target price on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Stock Performance

Shares of BSX stock opened at $53.02 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52 week low of $52.81 and a 52 week high of $109.50. The stock has a market capitalization of $78.80 billion, a PE ratio of 22.18, a P/E/G ratio of 0.99 and a beta of 0.62. The firm has a 50 day moving average of $64.19 and a two-hundred day moving average of $82.33.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s Seismiq intravascular lithotripsy program reached a first-patient milestone in the ELEGANCE registry, a modest positive signal for its interventional cardiology pipeline. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Positive Sentiment: Zacks highlighted continued cardiovascular growth, pointing to FARAPULSE and WATCHMAN momentum as key drivers of the company’s long-term growth story. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and shareholders approved governance changes, including eliminating supermajority voting provisions and adding limited officer exculpation. This may improve flexibility and align incentives, but it also signals share issuance potential. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Neutral Sentiment: Morningstar’s view that Boston Scientific is significantly undervalued after the recent share-price reset may attract value-oriented investors, but it does not remove near-term execution concerns. Boston Scientific (BSX) Valuation After Morningstar Downgrade And Significantly Undervalued Rating
• Negative Sentiment: Insiders sold about $1.2 million of shares, which can weigh on sentiment because it suggests some hesitation at current levels. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: The stock has underperformed competitors and recent commentary points to margin pressure and weaker estimates, helping explain why BSX is trading lower relative to peers. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.